RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Hikma Pharmaceuticals Stock

Hikma Pharmaceuticals Liabilities 2025

Hikma Pharmaceuticals Liabilities

2.48 B USD

Ticker

HIK.L

ISIN

GB00B0LCW083

WKN

A0HG69

In 2025, Hikma Pharmaceuticals's total liabilities amounted to 2.48 B USD, a 6.25% difference from the 2.34 B USD total liabilities in the previous year.

Hikma Pharmaceuticals Aktienanalyse

What does Hikma Pharmaceuticals do?

Hikma Pharmaceuticals PLC is a global company that focuses on the manufacturing and distribution of high-quality generics and specialty medications. The company was founded in Jordan in 1978 and is headquartered in London, UK. Over the years, Hikma Pharmaceuticals PLC has consistently grown and is now one of the leading generic manufacturers worldwide. The company operates in three core business areas: generics, injectables, and branded pharmaceuticals. It specializes in producing medications for diseases such as HIV/AIDS, cancer, and cardiovascular diseases. It also manufactures generics for anesthesia and opioid painkillers. In addition, Hikma Pharmaceuticals PLC produces injectable medications, particularly sterile injectables, used in emergency medicine, intensive care, and oncology. The company also develops proprietary medications based on specific patient needs and has its own pipeline of branded pharmaceuticals. It distributes over 1,000 medications in more than 50 countries, with production facilities in several countries including Jordan, Saudi Arabia, Portugal, Italy, and the United States. Hikma Pharmaceuticals PLC has shown strong performance in recent years, reflected in positive financial results. It prioritizes efficient production, strict quality standards, and smart investments to strengthen its market presence and innovation capability. The company has built a reputation as a reliable partner for customers and investors. In summary, Hikma Pharmaceuticals PLC is a global company engaged in the production and distribution of generics, injectables, and proprietary medications. It is known for its high-quality and cost-effective generics, broad product range, and strong international network. The company has established itself as a trusted partner for customers and investors and will continue to play a significant role in the pharmaceutical industry. Hikma Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Hikma Pharmaceuticals's Liabilities

Hikma Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Hikma Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Hikma Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Hikma Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Hikma Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Hikma Pharmaceuticals stock

What is the level of liabilities of Hikma Pharmaceuticals this year?

Hikma Pharmaceuticals has a debt balance of 2.48 B USD this year.

What were the liabilities of Hikma Pharmaceuticals compared to the previous year?

The liabilities of Hikma Pharmaceuticals have increased by 6.25% increased compared to the previous year.

What are the consequences of high debt for investors of Hikma Pharmaceuticals?

High liabilities can pose a risk for investors of Hikma Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Hikma Pharmaceuticals?

Low liabilities mean that Hikma Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Hikma Pharmaceuticals affect the company?

An increase in liabilities of Hikma Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Hikma Pharmaceuticals affect the company?

A decrease in the liabilities of Hikma Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Hikma Pharmaceuticals?

Some factors that can influence the liabilities of Hikma Pharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Hikma Pharmaceuticals so important for investors?

The liabilities of Hikma Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Hikma Pharmaceuticals take to modify the liabilities?

To change its liabilities, Hikma Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Hikma Pharmaceuticals pay?

Over the past 12 months, Hikma Pharmaceuticals paid a dividend of 0.49 USD . This corresponds to a dividend yield of about 2 %. For the coming 12 months, Hikma Pharmaceuticals is expected to pay a dividend of 0.52 USD.

What is the dividend yield of Hikma Pharmaceuticals?

The current dividend yield of Hikma Pharmaceuticals is 2 %.

When does Hikma Pharmaceuticals pay dividends?

Hikma Pharmaceuticals pays a quarterly dividend. This is distributed in the months of September, April, September, September.

How secure is the dividend of Hikma Pharmaceuticals?

Hikma Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Hikma Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0.52 USD are expected. This corresponds to a dividend yield of 2.11 %.

In which sector is Hikma Pharmaceuticals located?

Hikma Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hikma Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hikma Pharmaceuticals from 9/20/2024 amounting to 0.32 USD, you needed to have the stock in your portfolio before the ex-date on 8/16/2024.

When did Hikma Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/20/2024.

What was the dividend of Hikma Pharmaceuticals in the year 2024?

In the year 2024, Hikma Pharmaceuticals distributed 0.494 USD as dividends.

In which currency does Hikma Pharmaceuticals pay out the dividend?

The dividends of Hikma Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Hikma Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Hikma Pharmaceuticals

Our stock analysis for Hikma Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hikma Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.